Full Press Release Details
Hoth Therapeutics Announces $2.0 Million Registered
NEW YORK, April 1, 2026 - Hoth Therapeutics,
Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today
announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,857,144 shares of its common
stock (or common stock equivalents in lieu thereof) at an offering price of $0.70 per share of common stock (or per common stock equivalent
in lieu thereof), in a registered direct offering. Additionally, in a concurrent private placement, the Company issued and sold unregistered
warrants to purchase up to an aggregate of 2,857,144 shares of common stock at an exercise price of $0.85 per share. The unregistered
warrants will become exercisable six months following the date of issuance and will expire five and one-half years following the date
of issuance. The closing of the offering is expected to occur on or about April 2, 2026, subject to the satisfaction of customary closing
Co. is acting as the exclusive placement agent for the offering.
The aggregate gross proceeds
to the Company from the offering are expected to be approximately $2.0 million, before deducting the placement agent's fees and
other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the unregistered warrants,
if fully exercised on a cash basis, will be approximately $2.4 million. No assurance can be given that any of such unregistered warrants
will be exercised. The Company intends to use the net proceeds from this offering for general corporate purposes, including working capital.
The shares of common
stock (or common stock equivalents in lieu thereof) described above (but not the unregistered warrants issued in the concurrent private
placement and the shares issuable thereunder) are being offered and sold by the Company in a registered direct offering pursuant to a
"shelf" registration statement on Form S-3 (File No. 333-291566) that was originally filed with the Securities and Exchange
Commission (the "SEC") on November 17, 2015, and became effective on December 4, 2025. The offering of the shares of common
stock (or common stock equivalents in lieu thereof) in the registered direct offering is being made only by means of a base prospectus
and prospectus supplement that forms a part of the effective registration statement. A final prospectus supplement and the accompanying
base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC's website
at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying base prospectus, when available, may also be
obtained from H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.
The unregistered warrants
issued in the concurrent private placement and the shares issuable upon exercise of such warrants were offered in a private placement
under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and/or Regulation D promulgated thereunder, have
not been registered under the Act or applicable state securities laws and may not be offered or sold in the United States absent registration
or an applicable exemption from registration requirements.
This press release shall
not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale
of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such state or other jurisdiction.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is
a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to
improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench
to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians,
and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment
options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
These statements relate
to the consummation of the offering, the satisfaction of customary closing conditions related to the offering and the use of proceeds
This press release includes
forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of
the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject
to substantial risks, uncertainties, and assumptions. These statements relate to the consummation of the offering; the satisfaction of
customary closing conditions related to the offering; the use of proceeds from the offering and the potential exercise of the unregistered
warrants prior to their expiration; Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain
regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval
we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products;
the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research
programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations;
our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of
revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product
launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations,
including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could
cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these
forward-looking statements, which include words such as "could," "believe," "anticipate," "intend,"
"estimate," "expect," "may," "continue," "predict," "potential,"
"project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the
expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize
its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including, without limitation, market and other conditions and the factors described
in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the
U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements
should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking
statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and
specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future
events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Phone: (678) 570-6791